Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC
Brigatinib in Alectinib-Resistant ALK-Positive NSCLC
Updated USPSTF Recommendation on Lung Cancer Screening
Novel Bispecific PD-L1 and CTLA-4 Antibody for Metastatic NSCLC
Tyrosine Kinase Inhibitor Combination Therapy for HER2-Mutated NSCLC
Cemiplimab-rwlc Monotherapy and PD-L1 Expression in Advanced NSCLC
Do Tailored Chemotherapy Regimens Improve Outcomes in Early-Stage NSCLC?
FDA Expands Approval of Lorlatinib for ALK-Positive Non–Small Cell Lung Cancer
Tyrosine Kinase Inhibitor Therapy for Stage III EGFR-Mutated NSCLC
WCLC 2020: 3-Year Survival Update on Pembrolizumab for Locally Advanced or Metastatic NSCLC
WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC
FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC
WCLC 2020: Pembrolizumab Plus Chemotherapy for Metastatic NSCLC
Sotorasib Receives FDA Priority Review for KRAS G12C–Mutated Advanced Lung Cancer
WCLC 2020: KEYNOTE-799 Update on Pembrolizumab With Chemoradiotherapy in Stage III Lung Cancer
WCLC 2020: Updated Overall Survival With Atezolizumab in NSCLC From IMpower110
WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC
WCLC 2020: Genomic Analysis of Women With Lung Cancer Who Never Smoked
WCLC 2020: Adding Ipilimumab to Pembrolizumab for Metastatic NSCLC
Tepotinib Granted Accelerated Approval by FDA in Metastatic NSCLC
WCLC 2020: Small-Molecule Inhibitor Active in KRAS G12C–Mutated NSCLC
WCLC 2020: Novel Tyrosine Kinase Inhibitor Versus Chemotherapy for EGFR-Mutated NSCLC
Outcomes With Durvalumab After Chemoradiotherapy for NSCLC
JAVELIN Medley VEGF: Monoclonal Antibody Plus VEGFR Inhibitor Studied in NSCLC
FDA Brief: Zenocutuzumab Granted Fast Track Designation for NRG1 Fusion Cancers
Biomarker May Predict Susceptibility to Radiation Pneumonitis in Patients With Lung Cancer
Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC
Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?
Lorlatinib Receives Priority Review in Untreated ALK-Positive Lung Cancer
Adjuvant Osimertinib Approved by FDA for EGFR-Mutated Lung Cancer
Individualized Versus Standard Dosing of Radiotherapy in Stage III NSCLC
Stereotactic Body Radiotherapy for Larger Lung Tumors
First-Line Pembrolizumab Plus Niraparib in Advanced Metastatic NSCLC
Ramucirumab Plus Osimertinib in NSCLC: Final Analysis of Phase I Trial
Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC
Targeting KRAS Mutations in Advanced NSCLC: Early Trial Results
Capmatinib in MET-Dysregulated Advanced NSCLC: GEOMETRY Mono-1
ESMO Asia 2020: Adding PD-L1 Inhibitor to Platinum-Based Chemotherapy for NSCLC
Lorlatinib for First-Line Treatment of ALK-Positive NSCLC
SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma
SITC 2020: Vactosertib Plus Durvalumab in PD-L1–Positive NSCLC
ASTRO 2020: Pericardial Effusion and Survival With Radiation Therapies in Locally Advanced NSCLC
Timing of Brain Radiotherapy for NSCLC With Brain Metastasis
ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer
Equivalence Study of Bevacizumab Biosimilar in Metastatic Nonsquamous NSCLC
ASTRO 2020: Cardiac Events With Photon Versus Proton Radiotherapy for Lung Cancer
Lung Cancer and Severity of COVID-19: Experience From MSK
Osimertinib Receives Priority Review for EGFR-Mutant NSCLC
Early Clinical Data on Sotorasib in Advanced NSCLC
Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.